Linkedin Twitter Envelope

News

Home
/
/
Roche Pharma reviews the HTA Core Model® from a pharmaceutical perspective

Roche Pharma reviews the HTA Core Model® from a pharmaceutical perspective

In a report published in December 2014, Roche Pharma reviews the usefulness of the EUnetHTA Core model® for Roche’s internal HTA assembling, storing and sharing purposes.

In a report published in December 2014, Roche Pharma reviews the usefulness of the EUnetHTA Core model® for Roche’s internal HTA assembling, storing and sharing purposes.

The report focuses on the Pharmaceutical application of the HTA Core Model® and the value assessment of Pharmaceuticals.

Find the report and its appendices attached below.
appendix_5_unimportant_elements_3_5_wo_canada1

roche_pharma_report_on_the_hta_core_model_december2014_0
appendix_6_important_vers2_value_proposition_not_payers_wo_canada_korr6

appendix_2_unimportant_detail
appendix_3_oct_overall_important_elements_4_5_transferable_elements_4_5wo_canada1
appendix_4_important_elements_4_5_wo_canada

More news

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.

©2021 EUnetHTA All rights reserved.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.
Accept and Close